These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37127127)

  • 21. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.
    Wai AK; Chan CY; Cheung AW; Wang K; Chan SC; Lee TT; Luk LY; Yip ET; Ho JW; Tsui OW; Cheung KW; Lee S; Tong CK; Yamamoto T; Rainer TH; Wong EL
    Lancet Reg Health West Pac; 2023 Jan; 30():100602. PubMed ID: 36212676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study.
    Wai AK; Lee TT; Chan SC; Chan CY; Yip ET; Luk LY; Ho JW; So KW; Tsui OW; Lam ML; Lee SY; Yamamoto T; Tong CK; Wong MS; Wong EL; Rainer TH
    Sci Rep; 2023 May; 13(1):7832. PubMed ID: 37188726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
    Butler CC; Hobbs FDR; Gbinigie OA; Rahman NM; Hayward G; Richards DB; Dorward J; Lowe DM; Standing JF; Breuer J; Khoo S; Petrou S; Hood K; Nguyen-Van-Tam JS; Patel MG; Saville BR; Marion J; Ogburn E; Allen J; Rutter H; Francis N; Thomas NPB; Evans P; Dobson M; Madden TA; Holmes J; Harris V; Png ME; Lown M; van Hecke O; Detry MA; Saunders CT; Fitzgerald M; Berry NS; Mwandigha L; Galal U; Mort S; Jani BD; Hart ND; Ahmed H; Butler D; McKenna M; Chalk J; Lavallee L; Hadley E; Cureton L; Benysek M; Andersson M; Coates M; Barrett S; Bateman C; Davies JC; Raymundo-Wood I; Ustianowski A; Carson-Stevens A; Yu LM; Little P;
    Lancet; 2023 Jan; 401(10373):281-293. PubMed ID: 36566761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
    Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
    JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.
    Mali KR; Eerike M; Raj GM; Bisoi D; Priyadarshini R; Ravi G; Chaliserry LF; Janti SS
    Ir J Med Sci; 2023 Aug; 192(4):1665-1678. PubMed ID: 36087236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    medRxiv; 2022 Dec; ():. PubMed ID: 36561190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients.
    Poznański P; Augustyniak-Bartosik H; Magiera-Żak A; Skalec K; Jakuszko K; Mazanowska O; Janczak D; Krajewska M; Kamińska D
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C; Chai KL; Piechotta V; Valk SJ; Kimber C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Jindal A; Cryns N; Estcourt LJ; Kreuzberger N; Skoetz N
    Cochrane Database Syst Rev; 2023 May; 5(5):CD013600. PubMed ID: 37162745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
    Johnson MG; Puenpatom A; Moncada PA; Burgess L; Duke ER; Ohmagari N; Wolf T; Bassetti M; Bhagani S; Ghosn J; Zhang Y; Wan H; Williams-Diaz A; Brown ML; Paschke A; De Anda C
    Ann Intern Med; 2022 Aug; 175(8):1126-1134. PubMed ID: 35667065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19.
    Kauer V; Totschnig D; Waldenberger F; Augustin M; Karolyi M; Nägeli M; Wenisch C; Zoufaly A
    Viruses; 2023 May; 15(5):. PubMed ID: 37243267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.
    Gao Y; Liu M; Li Z; Xu J; Zhang J; Tian J
    Clin Microbiol Infect; 2023 Aug; 29(8):979-999. PubMed ID: 37084941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
    Goswami H; Alsumali A; Jiang Y; Schindler M; Duke ER; Cohen J; Briggs A; Puenpatom A
    Pharmacoeconomics; 2022 Jul; 40(7):699-714. PubMed ID: 35779197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.